A practical reference on c-Met receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-07 and is reviewed periodically as new material appears.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
In Algiers, the capital of Algeria, captured Christians and Europeans were forced into slavery. In about 1650, there were as many as 35,000 Christian slaves in Algiers. By one estimate, raids by Barbary slave traders on coastal villages and ships extending from Italy to Iceland, enslaved an estimated 1 to 1.25 million Europeans between the 16th and 19th centuries. However, this estimate is the result of an extrapolation which assumes that the number of European slaves captured by Barbary pirates was constant for a 250-year period:
Open to people of Lithuanian descent; sponsors Lithuanian cultural programs, gives aid to widows, and orphans, relief for victims of natural disasters, and awards scholarships. On July 1, 2012, the insurance aspects of the organization passed to the Croatian Fraternal Union. A Special Convention convened on September 22, 2012, authorized the leadership to reconstitute the LAA as a not-for-profit cultural group. Lithuanian Catholic Alliance - Founded in 1886 as the Lithuanian Roman Catholic Alliance of America, adopted its current name in 1975. Headquarters in Wilkes-Barre, Pennsylvania. National convention meets triennially. There were 163 lodges in 1972 and 147 in 1977. 1965 membership was 7,000, which declined to 4,000 in 1979. In 1994 there were 3,069 members, despite membership being opened to non-Catholics. Sponsors Lithuanian cultural activities, cookbooks, films, and radio programs; also sponsors scholarships for members, supports Community Chest, blood donor clinics, Catholic youth programs, youth camps, and Catholic Social Services.
Hexapeptide-10 (SIKVAV, Serilesine) is a hexapeptide that is composed of a sequence Ser-Ile-Lys-Val-Ala-Val found at the C-terminus of the laminin α1 chain. Unlike other matrikine peptides which primarily act in the epidermis, hexapeptide-10 is active in deeper skin layers and promotes synthesis of laminin and integrin proteins, increases secretion of matrix metalloproteinases MMP2 and MMP9, and has angiogenic effects. Hexapeptide-10 promotes wound healing and tissue remodeling, and is used in skincare products with purported anti-aging effects. It has also been investigated for potential medical applications in the treatment of conditions such as Alzheimer's disease and muscular dystrophy. Due to its ability to promote angiogenesis, it can also promote tumour growth and is used in cancer research, though this requires concentrations many times higher than those used in skincare products.
Interest in a possible island of stability grew throughout the 1960s, as some calculations suggested that it might contain nuclides with half-lives of billions of years. They were also predicted to be especially stable against spontaneous fission in spite of their high atomic mass. It was thought that if such elements exist and are sufficiently long-lived, there may be several novel applications as a consequence of their nuclear and chemical properties. These include use in particle accelerators as neutron sources, in nuclear weapons as a consequence of their predicted low critical masses and high number of neutrons emitted per fission, and as nuclear fuel to power space missions. These speculations led many researchers to conduct searches for superheavy elements in the 1960s and 1970s, both in nature and through nucleosynthesis in particle accelerators. During the 1970s, many searches for long-lived superheavy nuclei were conducted. Experiments aimed at synthesizing elements ranging in atomic number from 110 to 127 were conducted at laboratories around the world. These elements were sought in fusion-evaporation reactions, in which a heavy target made of one nuclide is irradiated by accelerated ions of another in a cyclotron, and new nuclides are produced after these nuclei fuse and the resulting excited system releases energy by evaporating several particles (usually protons, neutrons, or alpha particles).
11 (6): 5839–5848. Bibcode:2014IJERP..11.5839R. doi:10.3390/ijerph110605839. PMC 4078551. PMID 24886754. Saad, Mehdi; Psimaras, Dimitri; Tafani, Camille; Sallansonnet-Froment, Magali; Calvet, Jean-Henri; Vilier, Alice; Tigaud, Jean-Marie; Bompaire, Flavie; Lebouteux, Marie; de Greslan, Thierry; Ceccaldi, Bernard; Poirier, Jean-Michel; Ferrand, François-Régis; Le Moulec, Sylvestre; Huillard, Olivier; Goldwasser, François; Taillia, Hervé; Maisonobe, Thierry; Ricard, Damien (1 April 2016). "Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy". Journal of Neuro-Oncology. 127 (2): 373–380. doi:10.1007/s11060-015-2049-x. PMID 26749101. S2CID 19058905. Leclair-Visonneau, Laurène; Bosquet, Tristan; Magot, Armelle; Fayet, Guillemette; Gras-Le Guen, Christèle; Hamel, Antoine; Péréon, Yann (2016). "Electrochemical skin conductance for quantitative assessment of sweat function: Normative values in children". Clinical Neurophysiology Practice. 1: 43–45. doi:10.1016/j.cnp.2016.07.001. PMC 6123897. PMID 30214959. Shahani, B T; Halperin, J J; Boulu, P; Cohen, J (1 May 1984). "Sympathetic skin response--a method of assessing unmyelinated axon dysfunction in peripheral neuropathies". Journal of Neurology, Neurosurgery & Psychiatry. 47 (5): 536–542. doi:10.1136/jnnp.47.5.536. PMC 1027833. PMID 6330307. Caccia, MR; Dezuanni, E; Salvaggio, A; Osio, M; Bevilacqua, M; Norbiato, G; Mangoni, A (1991).
Sources: en.wikipedia.org
=== Post-Cold War === In late October 2019, a week before Commander of the Northern Fleet Aleksandr Moiseyev and Russian Foreign Minister Sergey Lavrov met their Norwegian counterparts in Kirkenes, Norway, ten submarines of Russia's Northern Fleet, among them two diesel-electric and eight non-strategic nuclear, left their homebases in the Kola Peninsula to participate in submarine drills that were the largest, on the Russian side, since Cold War operations Aport and Atrina. The main task of the submarines was reportedly testing Russian ability to breach the GIUK gap undetected and sail into the Atlantic Ocean. The drills were expected to last up to two months.
Endothelin 1 (ET-1), also known as preproendothelin-1 (PPET1), is the most potent vasoconstrictor produced by the human body. It is a peptide produced by vascular endothelial cells, as well as by cells in the heart (affecting contractility) and kidney (affecting sodium handling). The protein encoded by this gene – EDN1 – is proteolytically processed to release endothelin 1. Endothelin 1 is one of three isoforms of human endothelin.
== Dalton's chemical atomism == In 1804, John Dalton studied data gathered by himself and by other scientists and noticed a pattern that later came to be known as the law of multiple proportions: in compounds which contain two particular elements, the amount of Element A per measure of Element B will differ across these compounds by ratios of small whole numbers. For instance, Dalton investigated three oxides of nitrogen: "nitrous oxide", "nitrous gas", and "nitric acid". These compounds are known today as nitrous oxide, nitric oxide, and nitrogen dioxide respectively. "Nitrous oxide" is 63.3% nitrogen and 36.7% oxygen, which means it has 80 g of oxygen for every 140 g of nitrogen. "Nitrous gas" is 44.05% nitrogen and 55.95% oxygen, which means there are 160 g of oxygen for every 140 g of nitrogen. "Nitric acid" is 29.5% nitrogen and 70.5% oxygen, which means it has 320 g of oxygen for every 140 g of nitrogen. 80, 160, and 320 form a ratio of 1:2:4.
Quaternary structure the three-dimensional configuration of a protein molecule comprising several independent polypeptide chains. Secondary structure the interactions that occur between the C, O, and NH groups on amino acids in a polypeptide chain to form α-helices, β-sheets, turns, loops, and other forms, and that facilitate the folding into a three-dimensional structure. Superfamily a group of protein families of the same or different lengths that are related by distant yet detectable sequence similarity. Members of a given superfamily thus have a common evolutionary origin. Originally, Dayhoff defined the cutoff for superfamily status as being the chance that the sequences are not related of 10 6, on the basis of an alignment score (Dayhoff et al. 1978). Proteins with few identities in an alignment of the sequences but with a convincingly common number of structural and functional features are placed in the same superfamily. At the level of three-dimensional structure, superfamily proteins will share common structural features such as a common fold, but there may also be differences in the number and arrangement of secondary structures. The PIR resource uses the term homeomorphic superfamilies to refer to superfamilies that are composed of sequences that can be aligned from end to end, representing a sharing of single sequence homology domain, a region of similarity that extends throughout the alignment. This domain may also comprise smaller homology domains that are shared with other protein families and superfamilies.
Sources: en.wikipedia.org
==== Cruel and unusual ==== On occasion, difficulties inserting the intravenous needles have also occurred, with personnel sometimes taking over half an hour to find a suitable vein. Typically, the difficulty is found in convicts with type 2 diabetes or a history of intravenous drug use. Opponents argue that excessive time taken to insert intravenous lines is tantamount to cruel and unusual punishment. In addition, opponents point to instances where the intravenous line has failed or when adverse reactions to drugs or unnecessary delays have happened during the process of execution. On December 13, 2006, Angel Nieves Diaz was not executed successfully in Florida using a standard lethal-injection dose. Diaz was 55 years old and had been sentenced to death for murder. Diaz did not succumb to the lethal dose even after 35 minutes, necessitating a second dose of drugs to complete the execution. At first, a prison spokesman denied Diaz had suffered pain and claimed the second dose was needed because Diaz had some sort of liver disease. After performing an autopsy, the medical examiner, William Hamilton, stated that Diaz's liver appeared normal, but that the needle had pierced through Diaz's vein into his flesh. The deadly chemicals had subsequently been injected into soft tissue rather than into the vein.
Cider has also been popular in the Basque Country for centuries. While Txakoli and Rioja wines became more popular in Biscay, Álava, and Navarre during the 19th century, there is still a strong Basque cider culture in Gipuzkoa. From the 1980s, government and gastronomic associations have worked to revive this culture in all Basque regions. Known as sagardoa (IPA: /s̺a'gardoa/), it is drunk either bottled or in a cider house (called a sagardotegi), where it is poured from barrels. Most of "sagardotegis" are in the north of Gipuzkoa (Astigarraga, Hernani, Urnieta, and Usurbil), but they can be found everywhere in Gipuzkoa, the northwest of Navarre and the northern Basque country. Cider tasting events are popular in the Basque province of Gipuzkoa, where stalls are set up on the street selling the drink from several producers at cheap prices and served until stock runs out.
GABAergic pro-drugs include chloral hydrate, which is metabolised to trichloroethanol, which then acts via the GABAA receptor. The plant kava contains GABAergic compounds, including kavain, dihydrokavain, methysticin, dihydromethysticin and yangonin.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.